Co-Dx reports third quarter 2026 financial results
Revenue rose to $0.3 million while operating expenses fell 12% to $6.2 million; net loss was $6.3 million and cash totaled $0.7 million.
See the latest news and media coverage for Co-Dx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Real-time PCR diagnostic test developer
co-dx.comLast updated
In short: Co-Dx received a Peru test order as its CoSara joint venture submitted a tuberculosis test in India.
Revenue rose to $0.3 million while operating expenses fell 12% to $6.2 million; net loss was $6.3 million and cash totaled $0.7 million.
Management will discuss performance and business updates during an earnings call at 4:30 p.m. ET.
Revenue was $0.17M and the company filed a 510(k) for its respiratory test and expanded in Saudi Arabia.
Operating loss increased to $9.2 million, driven by R&D spending on clinical studies.
Co-Diagnostics, Inc. ( CODX) (CODX) revealed Loss for third quarter of -$6.306 million The company's earnings totaled -$6.306 million, or -$1.01 per share. This compares...
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...
On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. Earlier today,...
Net Loss -- $9.1 million, compared to $7.5 million, driven by higher operating expenses and reduced other income. Operating Expenses -- $9.2 million, compared to...
Track Co-Dx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Co-Dx and other trending companies.